Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.

Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Phase 3

Completed

Conditions: Schizophrenia
Psychotic Disorders

Interventions: Drug: Quetiapine
Drug: Aripiprazole
Drug: Risperidone Long Acting Injectable (LAI)

First Posted Date: 2005-09-22

Last Posted Date: 2014-04-16

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 753

Registration Number: NCT00216476

Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

Phase 4

Completed

Conditions: Bipolar Disorder
Alcohol Abuse/Dependence

Interventions: Drug: Quetiapine

First Posted Date: 2005-09-22

Last Posted Date: 2016-04-04

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 115

Registration Number: NCT00223249

Locations: 🇺🇸
The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents

Phase 3

Completed

Conditions: Mood Disorders

Interventions: Drug: quetiapine

First Posted Date: 2005-09-22

Last Posted Date: 2012-07-18

Lead Sponsor: University of Cincinnati

Target Recruit Count: 20

Registration Number: NCT00221468

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Seroquel on Glucose Metabolism

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2005-09-22

Last Posted Date: 2013-01-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 572

Registration Number: NCT00214578

Locations: 🇬🇧
Research Site, Birmingham, United Kingdom

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

Phase 4

Completed

Conditions: Cocaine Dependence
Bipolar Disorder

Interventions: Drug: PLacebo
Drug: Quetiapine

First Posted Date: 2005-09-22

Last Posted Date: 2012-08-20

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 100

Registration Number: NCT00223210

Locations: 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Quetiapine in Social Anxiety Disorder

Phase 2

Completed

Conditions: Social Anxiety Disorder

First Posted Date: 2005-09-22

Last Posted Date: 2006-12-19

Lead Sponsor: Duke University

Target Recruit Count: 15

Registration Number: NCT00215254

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Comparative Study of New Medications for Psychosis in Adolescents

Not Applicable

Completed

Conditions: Psychotic Disorders
Schizophrenia
Schizophreniform Disorders
Schizoaffective Disorders

First Posted Date: 2005-09-22

Last Posted Date: 2006-09-11

Lead Sponsor: University of Minnesota

Target Recruit Count: 30

Registration Number: NCT00222495

Locations: 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: quetiapine

First Posted Date: 2005-09-21

Last Posted Date: 2011-09-19

Lead Sponsor: Birte Glenthoj

Target Recruit Count: 46

Registration Number: NCT00207064

Locations: 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark
🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
🇩🇰
Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital, Hvidovre, Denmark